Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.C79yHELW.js ...
Vertex Pharmaceuticals forecast annual revenue largely above Wall Street estimates on Monday, banking on robust sales of its ...
The cystic fibrosis treatment leader exceeded revenue expectations, but missed slightly on earnings per share.
Vertex Pharmaceuticals (VRTX) reported fourth-quarter revenue and offered an outlook for 2025 that topped analysts’ ...
Fintel reports that on February 12, 2025, Canaccord Genuity upgraded their outlook for Vertex Pharmaceuticals (NasdaqGS:VRTX) ...
Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) reported Q4 CY2024 results exceeding the market’s revenue expectations, ...
The company posted quarterly adjusted earnings of $3.48 per share which missed the analyst consensus estimate of $4.03 per ...
Vertex Pharmaceuticals (VRTX) stock gets an upgrade from Canaccord Genuity after its Q4 2024 results on Tuesday, Read more here.
Biotechnology company Vertex Pharmaceuticals (VRTX) reported mixed results for the fourth quarter of 2024. While revenue surpassed analyst ...
Pfizer announced Jeffrey Legos, PhD, MBA as its new chief oncology officer. Bluejay Therapeutics announced Mary Cromwell, PhD, has joined its leadership team as SVP and head of technical operations.
Vertex Pharmaceuticals ( VRTX 2.53%) has long been known as the company to turn to for life-saving cystic fibrosis (CF) drugs ...
Piper Sandler analyst Christopher Raymond maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report) today and set a price ...